Valuation : Compugen Ltd.

Market Cap 246M 73.82B 213M 199M 182M 342M 23.49B 344M 2.36B 922M 11.88B 925M 904M 39.41B P/E 2026 *
-9.29x
P/E 2027 * -9.42x
Enterprise Value 246M 73.82B 213M 199M 182M 342M 23.49B 344M 2.36B 922M 11.88B 925M 904M 39.41B EV / Sales 2026 *
26.7x
EV / Sales 2027 * 31.8x
Free-Float
97.9%
Yield 2026 *
-
Yield 2027 * -
1 day-0.40%
1 week+4.12%
Current month+14.88%
1 month+13.67%
3 months+2.21%
6 months+48.36%
Current year+73.72%
1 week 749.6
Extreme 749.6
865
1 month 660
Extreme 660
865
Current year 485.2
Extreme 485.2
924
1 year 435
Extreme 435
924
3 years 208.1
Extreme 208.1
1,175
5 years 208.1
Extreme 208.1
2,358
10 years 208.1
Extreme 208.1
6,766
Manager TitleAgeSince
Chief Executive Officer - 23/09/2025
Director of Finance/CFO 42 15/08/2024
Chief Operating Officer 49 01/01/2024
Director TitleAgeSince
Chairman 59 23/09/2025
Director/Board Member 59 11/06/2018
Director/Board Member 70 11/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
-0.40%+4.12% - - 246M
-0.78%-1.42%+2.49%+22.78% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+16.15%+51.42% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.42%-1.03%+79.95%+111.62% 30.51B
Weighted average by Cap. -1.70%-1.08%+95.76%+129.66%

Financials

2026 *2027 *
Net sales 9.24M 2.77B 7.98M 7.48M 6.83M 12.84M 881M 12.91M 88.62M 34.6M 446M 34.69M 33.93M 1.48B 7.75M 2.32B 6.69M 6.27M 5.73M 10.77M 739M 10.83M 74.34M 29.02M 374M 29.1M 28.46M 1.24B
Net income -26.46M -7.93B -22.85M -21.42M -19.55M -36.79M -2.52B -36.97M -254M -99.11M -1.28B -99.35M -97.19M -4.24B -26.95M -8.08B -23.27M -21.81M -19.91M -37.46M -2.57B -37.65M -259M -101M -1.3B -101M -98.98M -4.31B
Net Debt - -
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
28/08/26 ILA 813.00 -0.40% 4,567
27/08/26 ILA 816.30 -5.15% 81,062
26/08/26 ILA 860.60 +7.95% 175,542
25/08/26 ILA 797.20 +5.12% 32,494
24/08/26 ILA 758.40 -2.87% 70,867
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.600USD
Average target price
4.600USD
Spread / Average Target
+76.92%

Quarterly revenue - Rate of surprise